I note there is an investor call set for 27th September when hopefully we can get a little more clarity about the trials, their duration, and the advantages of Being “fast tracked” and the possibilities around trial shortcuts etc, all of which will impact the first revenues from our first drug.
From the conversations to date with people’s close to the company who have been speaking to RH I have learnt the following.
Phase 1 trial will continue until mid 24, and be completed then. Phase 2 trial will run for 12 months from then, so completed mid 25. Phase 3 trial will then commence and run for 2 years but it is possible that early data will lead to an approval at an earlier time. What I am unclear about is exactly when that would be….. Information from the company suggests that revenues could be forthcoming from as early as the end of 2026.
I guess we wait until the investor call for clarification….
PYC Price at posting:
5.8¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)